Department of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Mol Cell Biochem. 2024 Dec;479(12):3293-3303. doi: 10.1007/s11010-024-04964-8. Epub 2024 Mar 2.
Metabolic diseases, such as obesity, diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD), are abnormal conditions that result from disturbances of metabolism. With the improvement of living conditions, the morbidity and mortality rates of metabolic diseases are steadily rising, posing a significant threat to human health worldwide. Therefore, identifying novel effective targets for metabolic diseases is crucial. Accumulating evidence has indicated that disulfide bond A oxidoreductase-like protein (DsbA-L) delays the development of metabolic diseases. However, the underlying mechanisms of DsbA-L in metabolic diseases remain unclear. In this review, we will discuss the roles of DsbA-L in the pathogenesis of metabolic diseases, including obesity, diabetes mellitus, and NAFLD, and highlight the potential mechanisms. These findings suggest that DsbA-L might provide a novel therapeutic strategy for metabolic diseases.
代谢性疾病，如肥胖症、糖尿病和非酒精性脂肪性肝病（NAFLD），是由代谢紊乱引起的异常情况。随着生活条件的改善，代谢性疾病的发病率和死亡率稳步上升，对全球人类健康构成重大威胁。因此，寻找新的有效的代谢性疾病靶点至关重要。越来越多的证据表明，二硫键 A 氧化还原酶样蛋白（DsbA-L）可延缓代谢性疾病的发展。然而，DsbA-L 在代谢性疾病中的作用机制尚不清楚。在本综述中，我们将讨论 DsbA-L 在肥胖症、糖尿病和 NAFLD 等代谢性疾病发病机制中的作用，并强调潜在的机制。这些发现表明，DsbA-L 可能为代谢性疾病提供一种新的治疗策略。
